SCHEMBL23705993

SCHEMBL23705993

O=C(O)N1CCc2ccc(C(F)F)cc2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.47
ESR2 Q92731 3/20 0.47
ACACB O00763 1/20 0.44
ABHD6 Q9BV23 2/20 0.43
MAPT P10636 3/20 0.42
KMT2A Q03164 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NOTUM Q6P988 1/20 0.41
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
NR1H2 P55055 1/20 0.40
F10 P00742 2/20 0.40
PLG P00747 2/20 0.40
PRSS1 P07477 2/20 0.40
PRSS2 P07478 2/20 0.40
PRSS3 P35030 2/20 0.40
KEAP1 Q14145 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30204981 0.94 ACACB (0.49) ESR1ESR2ACACBABHD6MAPT
SCHEMBL6648125 0.85 NR1H2 (0.44) ESR1ESR2MAPTKMT2ANPC1
SCHEMBL30097009 0.80 NR1H2 (0.67) ESR1ESR2ACACBABHD6MAPT
SCHEMBL25176924 0.80 NR1H2 (0.67) ESR1ESR2ACACBABHD6MAPT
SCHEMBL30261110 0.80 ALDH1A1 (0.51) ESR1ESR2KMT2ANPC1RAB9A
SCHEMBL23458633 0.78 PTPN2 (0.34) ESR1ESR2ACACBABHD6SMN1; SMN2
SCHEMBL1648634 0.78 ESR2 (0.68) ESR1ESR2ABHD6MAPTKMT2A
SCHEMBL30199245 0.78 ESR2 (0.68) ESR1ESR2ABHD6MAPTKMT2A
SCHEMBL23458643 0.77 ABHD6 (0.41) ESR1ESR2ACACBABHD6SMN1; SMN2
SCHEMBL2580108 0.77 ABCB1 (0.49) ESR1ESR2ACACBABHD6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115297861-B Compounds and uses thereof 福宏治疗公司 2024-07-12 CN disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
EP-4096667-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155320-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ESR1 3083/4885ESR2 1378/4885ACACB 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.